GSK 256073

Drug Profile

GSK 256073

Alternative Names: 256073; GSK-256073

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antihyperlipidaemics
  • Mechanism of Action G protein-coupled receptor agonists; GPR109A receptor agonists; Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Dyslipidaemias; Type 2 diabetes mellitus

Most Recent Events

  • 30 Sep 2011 Phase-II clinical trials in Type-2 diabetes mellitus (adjunctive treatment) in United Kingdom, France and Spain (PO)
  • 30 Sep 2011 Phase-II clinical trials in Type-2 diabetes mellitus in USA (PO)
  • 06 May 2010 GSK completes a phase II trial in Dyslipidaemia in the US (NCT00903617)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top